The recent announcement of a patent issuance has significantly enhanced investor confidence in Anew Medical, Inc. (NASDAQ: WENA). At close of the trading session on Thursday, WENA shares were experiencing a notable increase, trading at $1.28, a rise of 17.43% on the US stock charts.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Patent Grant for Innovative Genetic Treatments
Anew Medical has unveiled the grant of patent number HK1259628, which safeguards their novel genetic approaches aimed at treating neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS).
This crucial patent, previously announced for China, covers the use of ANEW’s Klotho protein and Klotho gene delivery and expression systems specifically for addressing cognitive, memory, and neurodegenerative conditions.
The intellectual property, exclusively licensed by Anew Medical from UNIVERSITAT AUTÒNOMA DE BARCELONA (UAB) and INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ICREA) in Barcelona, Spain, is protected on a global scale.
Market Impact and Strategic Importance
China, with the highest incidence of Alzheimer’s patients globally—nearly 10 million individuals aged 60 and above—is a key market for Anew Medical’s innovations. Additionally, Asia’s elderly population is expanding rapidly, with Japan projected to have approximately 6.5–7 million Alzheimer’s cases by 2025, paralleling the prevalence in the United States.
The impact of Alzheimer’s and related dementias is also significant in Western Europe, Finland, and North America, while Sub-Saharan Africa shows lower prevalence rates. African-Americans in the US face a higher likelihood of Alzheimer’s and other dementias compared to Caucasian and Hispanic Americans.
With intellectual property protection now established in Hong Kong, Beijing, Shanghai, and across the Chinese market, identifying clinical trial sites and forging corporate partnerships to evaluate the efficacy and safety of Anew Medical’s product candidates is critical.
The patented technology, encompassing the secreted form of the human Klotho protein (s-KL) delivered either as a protein or through gene sequence delivery, represents a significant advancement in the treatment and prevention of neurodegenerative diseases.
